Advertisement

MicroRNAs in endometrial cancers from black and white patients

Published:August 28, 2014DOI:https://doi.org/10.1016/j.ajog.2014.08.028

      Objective

      Previous studies have identified differences in gene mutations among endometrial cancers from whites and blacks suggesting that differences in tumor biology may explain racial disparities in patient outcome. Micro RNAs (miRNAs) have emerged as regulators of transcript expression and their aberrant expression has been discovered in many diseases, including endometrial cancer. We performed quantitative polymerase chain reaction–based analysis in a set of endometrial cancers to identify whether there are racial differences in miRNA expression.

      Study Design

      Tumor cells from 50 stage-I endometrioid endometrial cancer specimens from 41 white and 9 black patients were prepared by laser microdissection and miRNA extracts were analyzed using TaqMan (Life Technologies, Carlsbad, CA) low-density arrays. Statistically significant, differentially expressed miRNAs between blacks and whites were identified using multidimensional scaling, Wilcoxon testing, and analysis of variance.

      Results

      There were no global differences in miRNA expression between endometrial cancers from 41 white and 9 black patients. To minimize potential bias introduced by unbalanced sample size, we performed a subset analysis with stage- and histology-matched specimens from 9 whites and 9 blacks that identified 18 differentially abundant miRNAs (>2-fold at P < .005). Quantitative polymerase chain reaction validated miRNA-337-3p in an independent set of endometrial cancer specimens from 23 white and 24 black women. There were no racial differences in hsa-miR-337-3p expression in normal endometrium.

      Conclusion

      These data indicate that hsa-mir-337-3p is more frequently down-regulated in endometrial cancers from whites compared to blacks. Future studies are focused on determining the phenotypic impact of miR-337-3p and whether its differential expression is associated with clinical outcome.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sherman M.E.
        • Carreon J.D.
        • Lacey Jr., J.V.
        • Devesa S.S.
        Impact of hysterectomy on endometrial carcinoma rates in the United States.
        J Natl Cancer Inst. 2005; 97: 1700-1702
        • Sherman M.E.
        • Devesa S.S.
        Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus.
        Cancer. 2003; 98: 176-186
        • Hicks M.L.
        • Phillips J.L.
        • Parham G.
        • et al.
        The National Cancer Data Base report on endometrial carcinoma in African-American women.
        Cancer. 1998; 83: 2629-2637
        • Ghafoor A.
        • Jemal A.
        • Cokkinides V.
        • et al.
        Cancer statistics for African Americans.
        CA Cancer J Clin. 2002; 52: 326-341
        • Maxwell G.L.
        • Risinger J.I.
        Racial disparities research: it's not just black and white.
        Gynecol Oncol. 2006; 101: 194-197
        • Kohler M.F.
        • Carney P.
        • Dodge R.
        • et al.
        p53 Overexpression in advanced-stage endometrial adenocarcinoma.
        Am J Obstet Gynecol. 1996; 175: 1246-1252
        • Santin A.D.
        • Bellone S.
        • Siegel E.R.
        • et al.
        Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer.
        Am J Obstet Gynecol. 2005; 192: 813-818
        • Powell M.A.
        • Mutch D.G.
        • Rader J.S.
        • et al.
        Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker.
        Cancer. 2002; 94: 2941-2952
        • Suthipintawong C.
        • Wejaranayang C.
        • Vipupinyo C.
        Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
        J Med Assoc Thai. 2008; 91: 1779-1784
        • Maxwell G.L.
        • Risinger J.I.
        • Hayes K.A.
        • et al.
        Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers.
        Clin Cancer Res. 2000; 6: 2999-3005
        • Ferguson S.E.
        • Olshen A.B.
        • Levine D.A.
        • et al.
        Molecular profiling of endometrial cancers from African-American and Caucasian women.
        Gynecol Oncol. 2006; 101: 209-213
        • Risinger J.I.
        • Maxwell G.L.
        • Chandramouli G.V.
        • et al.
        Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling.
        Cancer Res. 2005; 65: 5031-5037
        • Maxwell G.L.
        • Chandramouli G.V.
        • Dainty L.
        • et al.
        Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.
        Clin Cancer Res. 2005; 11: 4056-4066
        • Risinger J.I.
        • Maxwell G.L.
        • Chandramouli G.V.
        • et al.
        Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer.
        Cancer Res. 2003; 63: 6-11
        • Risinger J.I.
        • Allard J.
        • Chandran U.
        • et al.
        Gene expression analysis of early stage endometrial cancers reveals unique transcripts associated with grade and histology but not depth of invasion.
        Front Oncol. 2013; 3: 139
        • Maxwell G.L.
        • Allard J.
        • Gadisetti C.V.
        • et al.
        Transcript expression in endometrial cancers from black and white patients.
        Gynecol Oncol. 2013; 130: 169-173
        • Menashe I.
        • Anderson W.F.
        • Jatoi I.
        • Rosenberg P.S.
        Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis.
        J Natl Cancer Inst. 2009; 101: 993-1000
        • DeLancey J.O.
        • Thun M.J.
        • Jemal A.
        • Ward E.M.
        Recent trends in black-white disparities in cancer mortality.
        Cancer Epidemiol Biomarkers Prev. 2008; 17: 2908-2912
        • Jatoi I.
        • Anderson W.F.
        • Rao S.R.
        • Devesa S.S.
        Breast cancer trends among black and white women in the United States.
        J Clin Oncol. 2005; 23: 7836-7841
        • Tammemagi C.M.
        • Nerenz D.
        • Neslund-Dudas C.
        • Feldkamp C.
        • Nathanson D.
        Comorbidity and survival disparities among black and white patients with breast cancer.
        JAMA. 2005; 294: 1765-1772
        • Long B.
        • Liu F.W.
        • Bristow R.E.
        Disparities in uterine cancer epidemiology, treatment, and survival among African Americans in the United States.
        Gynecol Oncol. 2013; 130: 652-659
        • Allard J.E.
        • Maxwell G.L.
        Race disparities between black and white women in the incidence, treatment, and prognosis of endometrial cancer.
        Cancer Control. 2009; 16: 53-56
        • Yap O.W.
        • Matthews R.P.
        Racial and ethnic disparities in cancers of the uterine corpus.
        J Natl Med Assoc. 2006; 98: 1930-1933
        • Maxwell G.L.
        • Tian C.
        • Risinger J.
        • et al.
        Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study.
        Cancer. 2006; 107: 2197-2205
        • Reddy S.
        • Shapiro M.
        • Morton Jr., R.
        • Brawley O.W.
        Prostate cancer in black and white Americans.
        Cancer Metastasis Rev. 2003; 22: 83-86
        • Burks D.A.
        • Littleton R.H.
        The epidemiology of prostate cancer in black men.
        Henry Ford Hosp Med J. 1992; 40: 89-92
        • Olopade O.I.
        • Grushko T.A.
        • Nanda R.
        • Huo D.
        Advances in breast cancer: pathways to personalized medicine.
        Clin Cancer Res. 2008; 14: 7988-7999
        • Kang S.P.
        • Martel M.
        • Harris L.N.
        Triple negative breast cancer: current understanding of biology and treatment options.
        Curr Opin Obstet Gynecol. 2008; 20: 40-46
        • Timofeeva O.A.
        • Zhang X.
        • Ressom H.W.
        • et al.
        Enhanced expression of SOS1 is detected in prostate cancer epithelial cells from African-American men.
        Int J Oncol. 2009; 35: 751-760
        • Desai K.V.
        • Kavanaugh C.J.
        • Calvo A.
        • Green J.E.
        Chipping away at breast cancer: insights from microarray studies of human and mouse mammary cancer.
        Endocr Relat Cancer. 2002; 9: 207-220
        • Allard J.E.
        • Chandramouli G.V.
        • Stagliano K.
        • et al.
        Analysis of PSPHL as a candidate gene influencing the racial disparity in endometrial cancer.
        Front Oncol. 2012; 2: 65
        • Morrison C.
        • Miecznikowski J.
        • Darcy K.M.
        • et al.
        A GOG 210 aCGH study of gain at 1q23 in endometrioid endometrial cancer in the context of racial disparity and outcome.
        Genes Chromosomes Cancer. 2010; 49: 791-802
        • Clifford S.L.
        • Kaminetsky C.P.
        • Cirisano F.D.
        • et al.
        Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer.
        Am J Obstet Gynecol. 1997; 176: S229-S232
        • Cote M.L.
        • Atikukke G.
        • Ruterbusch J.J.
        • et al.
        Racial differences in oncogene mutations detected in early-stage low-grade endometrial cancers.
        Int J Gynecol Cancer. 2012; 22: 1367-1372
        • Wincewicz A.
        • Baltaziak M.
        • Kanczuga-Koda L.
        • et al.
        STAT3 and apoptosis regulators: Bak and Bcl-xL in endometrioid adenocarcinomas of different estrogen receptor-alpha immunoprofile.
        Gynecol Endocrinol. 2011; 27: 536-540
        • Tang J.Z.
        • Kong X.J.
        • Banerjee A.
        • et al.
        STAT3alpha is oncogenic for endometrial carcinoma cells and mediates the oncogenic effects of autocrine human growth hormone.
        Endocrinology. 2010; 151: 4133-4145
        • Wincewicz A.
        • Koda M.
        • Sulkowska M.
        • Kanczuga-Koda L.
        • Sulkowski S.
        Comparison of STAT3 with HIF-1alpha, Ob and ObR expressions in human endometrioid adenocarcinomas.
        Tissue Cell. 2008; 40: 405-410
        • Pallares J.
        • Martinez-Guitarte J.L.
        • Dolcet X.
        • et al.
        Survivin expression in endometrial carcinoma: a tissue microarray study with correlation with PTEN and STAT-3.
        Int J Gynecol Pathol. 2005; 24: 247-253